After months of preparation and close collaboration with patient advocacy groups, patients and carers, we are proud to launch our European patient survey on CAR T-cell therapy! This survey will help us to understand patients’ experiences with CAR T-cell therapy, evaluate the impact on quality of life and identify unmet needs. With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.

All European adult patients who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.

Now, we need you!

If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!

If you are not a patient but in close contact with patients who receive CAR T-cell therapy (e.g. a patient association, hematologist, nurse or other healthcare professional) we would like to invite you to help us by sharing this survey with patients!

The survey is currently available in English, French, German and Portuguese and will soon be available in Spanish, Italian, Greek and Dutch.

A separate survey for informal caregivers is being developed and will be based on this patient survey.

2 WAYS TO ACCESS & SHARE THE SURVEY
(before end of September)

Password to enter the survey:
T2EVOLVE-QUALITOP

Share This